ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.110,38
-0,16%
S&P 500
5.667,20
0,64%
US Dollar vs BRL
5,4259
-0,41%
Bitcoin
65.126,04
0,42%
Brent Oil
83,315
-1,22%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Allos Therapeutics, Inc. (MM) (ALTH)

  7. Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH
DataHoraFonteTítuloCódigoCompanhia
17/06/201107:50GlobeNewswire Inc.Allos Therapeutics is MicroStockProfit.com's Biopharm Feature StockNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/06/201103:30Business WireData Suggests Treatment with FOLOTYN® Reverses Trend of Progressive Resistance Observed in Patients with Drug-Resistant Rela...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/06/201103:30Business WireCOMPLETE Registry Provides First Glance into Treatment Patterns for Patients with Peripheral T-Cell LymphomaNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
08/06/201110:00Business WireFOLOTYN® Data to be Presented at the Congress of the European Hematology Association & the International Conference on Malig...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/06/201116:57Edgar (US Regulatory)Amended Statement of Ownership (SC 13G/A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
20/05/201113:49ZacksRisk-Reward Balanced at Allos - Analyst BlogNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
16/05/201117:14Edgar (US Regulatory)Current report filing (8-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
13/05/201113:55Zacks1Q Loss Narrows at Allos - Analyst BlogNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/05/201118:24Edgar (US Regulatory)Quarterly Report (10-Q)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/05/201117:05Business WireAllos Therapeutics and Mundipharma Announce Strategic Collaboration for FOLOTYNNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/05/201117:00Business WireAllos Therapeutics Reports First Quarter 2011 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
06/05/201115:42ZacksMixed Results for CELG's Revlimid - Analyst BlogNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/05/201109:00Business WireAllos Therapeutics to Present at Upcoming Investor Conferences in MayNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/05/201109:00Business WireAllos Therapeutics to Report First Quarter 2011 Results on May 10, 2011NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
02/05/201109:16MarketwiredOncology Drug Makers Positioned for Long Term GrowthNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/04/201117:48Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/04/201113:35Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (DEFA14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
29/04/201113:31Edgar (US Regulatory)Proxy Statement (definitive) (DEF 14A)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
05/04/201114:01ZacksAllos Therapeutics at Neutral - Analyst BlogNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
04/04/201112:20ZacksCancer Study to Continue at SPPI - Analyst BlogNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
30/03/201109:00Business WireAllos Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/03/201108:35MarketwiredSpeculative Biotech Firms Remain Popular Takeover TargetsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/201118:20Edgar (US Regulatory)Annual Report (10-K)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/201118:00Business WireAllos Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of FOLOTYN in Patients with Pre...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
03/03/201118:00Business WireAllos Therapeutics Reports Fourth Quarter and Full Year 2010 Financial ResultsNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
17/02/201112:00Business WireAllos Therapeutics to Report Fourth Quarter and Full Year 2010 Results on March 3, 2011NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
10/02/201117:37Edgar (US Regulatory)Statement of Ownership (SC 13G)NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
19/01/201121:31Business WireJournal of Clinical Oncology Publishes Results from Pivotal Phase 2 PROPEL Study of FOLOTYN® in Relapsed or Refractory Perip...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
11/01/201111:00Business WireAllos Therapeutics Reports 2010 Financial Highlights and 2011 Key Business PrioritiesNASDAQ:ALTHAllos Therapeutics, Inc. (MM)
21/12/201011:00Business WireAllos Therapeutics’ Marketing Authorisation Application (MAA) for FOLOTYN® Accepted for Review by European Medicines Agenc...NASDAQ:ALTHAllos Therapeutics, Inc. (MM)
 Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

Seu Histórico Recente

BOV
HAGA3
HAGA ON
BOV
IBOV
Índice Bovespa
BOV
TELB4
TELEBRAS PN
BOV
AZEV4
AZEVEDO PN
BOV
GFSA3
GAFISA ON
BOV
AMER3
Americanas ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
COGN3
COGNA ON
BOV
NGRD3
Neogrid Participacoes ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
VVEO3
CM Hospitalar ON
BOV
AMAR3
LOJAS MARISA ON
BOV
JFEN3
JOAO FORTES ON
BOV
GOLL4
GOL PN
BOV
HBOR3
HELBOR ON
BOV
AGXY3
Agrogalaxy Participacoes ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados